Antibiotic Prophylaxis With Complement Inhibitors in Myasthenia Gravis

Key Takeaways:

• Meningococcal vaccination is the cornerstone of infection prevention in patients receiving complement inhibitors. When treatment must begin before vaccine-induced immunity develops, short-term antibacterial prophylaxis is recommended.
• Because several antibiotics can worsen MG, antimicrobial selection requires additional consideration. Expert consensus favors rifampicin for prophylaxis and ceftriaxone for suspected meningococcal infection, although recommendations may vary by region and local resistance patterns.
• A residual risk of invasive meningococcal disease persists throughout treatment and for months after discontinuation, making patient education and prompt recognition of symptoms essential.

Terminal complement inhibition has transformed the treatment of acetylcholine receptor (AChR) antibody-positive gMG, but it carries a defined and dangerous trade-off. By blocking the C5-dependent membrane attack complex, complement inhibitors impair one of the immune system's primary mechanisms for clearing Neisseria meningitidis, raising the risk of invasive meningococcal disease (IMD).¹

Every clinician who prescribes these agents must therefore pair them with a deliberate infection-prevention strategy.

Why the risk profile changes

The rationale is mechanistic. Terminal complement is central to host defense against encapsulated Neisseria species, so pharmacologic C5 blockade creates a susceptibility similar to that seen in inherited terminal complement deficiency.¹

Reassuringly, real-world pharmacovigilance data covering more than 125,000 patient-years of eculizumab and ravulizumab exposure show that structured risk mitigation keeps event rates low-meningococcal infection rates were roughly 0.10 to 0.25 per 100 patient-years in 2024, with meningococcal-associated mortality at or below 0.03 per 100 patient-years. These findings likely reflect the impact of vaccination, prophylaxis, and ongoing clinical vigilance rather than elimination of the underlying biologic risk.³

Vaccination as the foundation

Meningococcal vaccination against serogroups A, C, W, Y (MenACWY) and serogroup B (MenB) is recommended for all patients starting complement inhibitors. Product labeling and expert consensus describe 3 common approaches depending on clinical urgency.¹

In the preferred approach for MG, vaccination is completed at least 14 days before the first dose, allowing immunity to develop before complement is blocked. When treatment cannot wait, vaccination and therapy begin concurrently, or therapy precedes vaccination – and in both of those scenarios, antibiotic prophylaxis is required.¹

When antibiotics enter the plan

Antibacterial prophylaxis becomes particularly important when complement inhibition cannot be delayed long enough for protective immunity to develop. Because gMG often demands prompt disease control, many patients cannot complete a 2-week pre-vaccination window, so antibiotic prophylaxis covers the interval until day 14 after vaccination.¹

Prophylaxis is also warranted beyond that bridging period in specific circumstances: Asplenic patients require long-term prophylaxis alongside vaccination, and patients receiving B-cell-depleting therapies may have diminished vaccine responses, and prolonged prophylaxis may be reasonable on a case-by-case basis.¹

Importantly, ongoing immunosuppression by itself does not mandate indefinite prophylaxis when vaccination is current. The value of layering protection is supported by cohort data in C5-inhibitor-treated patients, where combined vaccination plus continuous antibiotic prophylaxis was associated with lower rates of invasive meningococcal disease than either strategy alone, although these data are observational.^1,4

Regimen choices specific to MG

Agent selection in MG cannot be borrowed wholesale from other indications, because several first-line antimeningococcal antibiotics can precipitate myasthenic worsening. Penicillin V, penicillin G, and azithromycin all carry the potential to exacerbate MG and should be used cautiously when reasonable alternatives are available.¹

Based on this expert consensus, rifampicin for antibiotic prophylaxis (typically dosed over 2 consecutive days every 14 days), ceftriaxone as first-line treatment for a suspected acute infection, and rifampicin or intramuscular ceftriaxone for post-exposure chemoprophylaxis. Local antimicrobial resistance patterns should inform final choices, particularly given rising ciprofloxacin resistance in some regions.¹

Vigilance and the residual risk

Despite appropriate vaccination and prophylaxis, breakthrough meningococcal infection can still occur. Breakthrough infection remains possible despite full vaccination and prophylaxis, and elevated risk persists after discontinuation until complement activity has recovered.¹

Patients should be educated about the early symptoms of meningococcal disease and instructed to seek immediate medical attention if symptoms develop. An emergency information card, standby antibiotics when appropriate, and recommended booster vaccinations provide additional layers of protection.¹

In sum, protecting gMG patients on complement inhibitors rests on 3 coordinated pillars:

• Complete MenACWY and MenB vaccination
• Antibiotic prophylaxis to bridge incomplete or urgent coverage
• Sustained clinical vigilance

What sets MG apart is the need to choose agents that do not aggravate the underlying disease while also considering the potential for certain antibiotics to worsen neuromuscular transmission. Antibiotic selection should balance meningococcal coverage with MG-specific safety considerations, local resistance patterns, and infectious disease guidance.